Diffusion Pharmaceuticals (NASDAQ:DFFN) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.
This is a breakdown of recent ratings for Diffusion Pharmaceuticals and VBI Vaccines, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Diffusion Pharmaceuticals has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500.
This table compares Diffusion Pharmaceuticals and VBI Vaccines’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Diffusion Pharmaceuticals and VBI Vaccines’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Diffusion Pharmaceuticals||N/A||N/A||-$1.36 million||($1.14)||-0.29|
|VBI Vaccines||$860,000.00||153.46||-$38.99 million||N/A||N/A|
Diffusion Pharmaceuticals has higher earnings, but lower revenue than VBI Vaccines.
Insider & Institutional Ownership
7.4% of Diffusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of VBI Vaccines shares are owned by institutional investors. 5.8% of Diffusion Pharmaceuticals shares are owned by company insiders. Comparatively, 54.5% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
VBI Vaccines beats Diffusion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
VBI Vaccines Company Profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.